Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olverembatinib + Blinatumomab in Ph+ ALL
NCT05931757Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jul 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olverembatinib in acute lymphoblastic leukemia (ALL), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Number of Participants with Complete Molecular Remission at 16 weeks. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
olverembatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05931757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05931757.